{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:22:43Z","timestamp":1783606963642,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Diethylcarbamazine citrate (DEC) treatment of loiasis is complicated by adverse reactions that are correlated with the number of circulating microfilariae (mf). The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To explore the role of IL-5 driven eosinophilia in post-DEC reactions, 8 adults with confirmed loiasis and &amp;lt;5000 mf\/mL blood were enrolled in a randomized, double-blind, placebo-controlled trial of the humanized anti-IL-5 antibody, reslizumab, (1.0 mg\/kg IV) administered 3 to 7 days prior to initiation of DEC treatment (9 mg\/kg\/day for 21 days). The primary endpoint was the reduction in absolute eosinophil count (AEC) during the first week of DEC treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline characteristics were comparable between the two groups. Single dose reslizumab lowered the AEC by 77% prior to initiation of DEC therapy (vs. 12% in the placebo group, P\u2005&amp;lt;\u2005.05). More importantly, AEC remained below baseline in the first week of DEC treatment in all subjects who received reslizumab and in none of the placebo subjects. Mf clearance occurred within 2 days of initiation of DEC in all 7 mf-positive subjects. Mild to moderate adverse events were seen in all 8 subjects and were not significantly different between the groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In summary, although reslizumab was able to blunt peripheral eosinophilia post-DEC treatment in subjects with loiasis and had no effect on microfilarial clearance, the reduction in AEC appeared to have been insufficient to prevent post-treatment AEs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1365","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T19:14:27Z","timestamp":1599506067000},"page":"e1624-e1631","source":"Crossref","is-referenced-by-count":14,"title":["A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of <i>Loa loa<\/i> Infection"],"prefix":"10.1093","volume":"73","author":[{"given":"Fanny","family":"Legrand","sequence":"first","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesica","family":"Herrick","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"},{"name":"Division of Infectious Diseases, Immunology and International Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Makiya","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"},{"name":"Emergent Biosolutions, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reagan","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Virginia Family Medicine, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakuntala","family":"Rampertaap","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Warren Magnusson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Stoddard","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Warren Magnusson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JeanAnne","family":"Ware","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Fay","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Holland-Thomas","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B","family":"Nutman","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy D","family":"Klion","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"2021121702384825100_CIT0001","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4269\/ajtmh.1995.52.370","article-title":"Longitudinal survey of Loa loa filariasis in southern Cameroon: long-term stability and factors influencing individual microfilarial status","volume":"52","author":"Garcia","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"2021121702384825100_CIT0002","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/infdis\/163.6.1318","article-title":"Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation","volume":"163","author":"Klion","year":"1991","journal-title":"J Infect Dis"},{"key":"2021121702384825100_CIT0003","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/infdis\/169.3.604","article-title":"Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up","volume":"169","author":"Klion","year":"1994","journal-title":"J Infect Dis"},{"key":"2021121702384825100_CIT0004","article-title":"Infection-associated immune perturbations resolve one year following treatment for Loa loa","author":"Herrick","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021121702384825100_CIT0005","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/167.6.1396","article-title":"Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis","volume":"167","author":"Limaye","year":"1993","journal-title":"J Infect Dis"},{"key":"2021121702384825100_CIT0006","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/cid\/cix016","article-title":"Posttreatment reactions after single-dose diethylcarbamazine or ivermectin in subjects with Loa loa infection","volume":"64","author":"Herrick","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021121702384825100_CIT0007","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(01)06899-4","article-title":"Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood","volume":"358","author":"Cross","year":"2001","journal-title":"Lancet"},{"key":"2021121702384825100_CIT0008","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/infdis\/169.5.1071","article-title":"Interleukin-6 and tumor necrosis factor in the pathogenesis of adverse reactions after treatment of lymphatic filariasis and onchocerciasis","volume":"169","author":"Turner","year":"1994","journal-title":"J Infect Dis"},{"key":"2021121702384825100_CIT0009","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.1961.10.849","article-title":"The effect of prednisone on persistent microfilaremia during treatment with diethylcarbamazine","volume":"10","author":"Schofield","year":"1961","journal-title":"Am J Trop Med Hyg"},{"key":"2021121702384825100_CIT0010","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"2021121702384825100_CIT0011","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1371\/journal.pntd.0001299","article-title":"Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia","volume":"5","author":"Fink","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121702384825100_CIT0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2014.05.020","article-title":"Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins","volume":"411","author":"Makiya","year":"2014","journal-title":"J Immunol Methods"},{"key":"2021121702384825100_CIT0013","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2011.05.032","article-title":"IL-5 receptor \u03b1 levels in patients with marked eosinophilia or mastocytosis","volume":"128","author":"Wilson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2021121702384825100_CIT0014","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0169-4758(96)40006-0","article-title":"Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas","volume":"12","author":"Chippaux","year":"1996","journal-title":"Parasitol Today"},{"key":"2021121702384825100_CIT0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/cid\/ciu723","article-title":"Eosinophil-associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to Loa-endemic areas","volume":"60","author":"Herrick","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021121702384825100_CIT0016","first-page":"77","article-title":"Does dexamethasone suppress the Mazzotti reaction in patients with onchocerciasis?","volume":"45","author":"Stingl","year":"1988","journal-title":"Acta Trop"},{"key":"2021121702384825100_CIT0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4269\/ajtmh.1958.7.185","article-title":"The effect of cortisone and prednisone on bullous reactions following treatment of filariasis with diethylcarbamazine","volume":"7","author":"March","year":"1958","journal-title":"Am J Trop Med Hyg"},{"key":"2021121702384825100_CIT0018","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4269\/ajtmh.1991.44.684","article-title":"Five cases of encephalitis during treatment of loiasis with diethylcarbamazine","volume":"44","author":"Carme","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"2021121702384825100_CIT0019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/jnnp.18.2.103","article-title":"Encephalitis in loa-loa filariasis","volume":"18","author":"van Bogaert","year":"1955","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021121702384825100_CIT0020","doi-asserted-by":"crossref","first-page":"e0004202","DOI":"10.1371\/journal.pntd.0004202","article-title":"Parasitological, hematological and biochemical characteristics of a model of hyper-microfilariaemic loiasis (Loa loa) in the baboon (Papio anubis)","volume":"9","author":"Wanji","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2021121702384825100_CIT0021","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/bmj.287.6391.519","article-title":"Usefulness of apheresis to extract microfilarias in management of loiasis","volume":"287","author":"Muylle","year":"1983","journal-title":"Br Med J (Clin Res Ed)"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1365\/34927814\/ciaa1365.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e1624\/41795163\/ciaa1365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e1624\/41795163\/ciaa1365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T02:39:17Z","timestamp":1639708757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/7\/e1624\/5903700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,9,10]]},"published-print":{"date-parts":[[2021,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1365","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,9,10]]}}}